Our main aim is to aid in the fight to cure cancer using advanced chemotherapy. Cancer is one of the largest killer diseases worldwide. For many years Medical Oncologists have been developing different protocols to help their patients fight this disease. Many types of cancers are cured totally by chemotherapy.

In fulfilling our social responsibility Amronco Lifesciences Ltd. has set up its Oncology division in order to offer high quality chemotherapy drugs at affordable prices to the patients.

Our research team are focused in the areas of chemotherapy, biotech recombinant products & developing novel drug delivery systems using nanotechnology & peptide based target specific chemotherapy.

We have a presence in the field of biotech recombinant products viz., rGCSF (Filgrastim) for Ukraine. Our rGCSF brand Filgrast in 300mcg & 480mcg was registered by the Ukrainian Health Authorities & accorded marketing permission in April 2005.

We are also working on generic versions of recombinant monoclonal antibodies We intend to market these products in the domestic markets as well as in our overseas markets.

R&D - New Drug Delivery platforms are being developed for administration of chemotherapy drugs using combination of existing establised technologies to reduce the side effects of chemotherapy agents when administered. Biotech research for the development of biosimilar clones for existing biopharmaceuticals products